Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NCD Partnership

- PMLiVE

Blue Latitude’s industry-first praised at PMEA

Support for Lilly and its Medical Information Cascade wins Innovation Award

- PMLiVE

Novo Nordisk says Victoza outperforms SGLT2 inhibitors

Comparesthe GLP-1 agonist to Invokana, Jardiance and Farxiga

Eli Lilly HQ

FDA clears Lilly’s lung cancer drug Portrazza

First biologic drug to be approved as first-line therapy for NSCLC

- PMLiVE

J&J and Hanmi collaborate on diabetes and obesity

Alliance worth up to$915m

Eli Lilly HQ

Sanofi and Lilly highlight rheumatoid arthritis hopefuls at ACR

Top-line results for sarilumab and baricitinib

- PMLiVE

US government probes Lilly and Merck over drug pricing

Department of Justice investigates drug pricing with regard to Medicaid programme

Sanofi reception

Sanofi and Lexicon collaborate on new medication for diabetes

Plan to develop new investigational drugsotagliflozin

Sanofi reception

Sanofi and Hanmi collaborate on diabetes treatments

Aims to optimise efficacy of medications

Eli Lilly HQ

Lilly and AZ forge closer immuno-oncology bond

Look to boost their presence in a market predicted to be worth $30bn in 10 years

- PMLiVE

Novo Nordisk finally bags insulin degludec approval in US

Aims to get Tresiba and Ryzodeg back on course 

- PMLiVE

FDA rejects AZ’s diabetes combination

Wants to see more trial data on saxagliptin / dapagliflozin

- PMLiVE

Lilly’s baricitinib beats Humira in trial for RA

Posts positive phase III data against the world's biggest-selling drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links